Stanley Druckenmiller Invests Heavily in Genomics Firm Natera
- Druckenmiller’s Duquesne Family Office allocated about 17% of its US stock holdings to Natera (NTRA).
- Natera processed over one million tests in Q2, including a year-over-year increase of 56% in oncology tests.
- The company’s revenue reached $753 million, up by 38% from the previous year.
- Druckenmiller began acquiring NTRA shares in Q3 of the previous year at prices between $35 and $50.
- NTRA is now Druckenmiller’s largest single US equity position within a $5.2 billion portfolio.
This strategic move reflects a shift towards healthcare investments over traditional tech stocks like Nvidia, which was sold due to valuation concerns. The focus on genomics aligns with growing trends in personalized medicine and diagnostics, marking a significant pivot for the family office.
Druckenmiller’s investment in Natera showcases confidence in the healthcare sector’s growth potential, especially as the stock has surged nearly tenfold since his initial purchases. (Source)
